Evaluating the effect of new remedy IMOD (Imunomodulating Drug)in the treatment of adult patients with sever sepsis

Phase 2

• Conditions: Severe sepsis; Blood - Other blood disorders

• Registration Number: ACTRN12607000376448
• Lead Sponsor: Tehran University of Medical Sciences,faculty of pharmacy

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2007-07-16
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

1.severe sepsis2.APACHE(Acute physiologic and chronic health evaluation) Score>203.Less than 24 hours from the diagnosis of sepsis.

Exclusion Criteria

1.Pregnant patients2.lactating women3.age<18 years old4.>24 hours from the diagnosis of sepsis

Study & Design

• Study Type: Interventional
• Study Design: Not specified